CRDL Logo

Cardiol Therapeutics Inc. (CRDL) Stock Forecast & Price Prediction

Live CRDL Stock Price & Analysis

Home โ€บ Stocks โ€บ Canada | NASDAQ | Healthcare | Drug Manufacturers - Specialty & Generic

$1.35

-0.10 (-6.90%)

12 Month Price Forecast For CRDL

$1.35
Current Price
$110.16M
Market Cap
5 Ratings
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to CRDL Price Forecasts

+628.2%
To High Target of $9.83
+541.5%
To Median Target of $8.66
+480.8%
To Low Target of $7.84

CRDL Price Momentum

-4.3%
1 Week Change
+0.7%
1 Month Change
+25.0%
1 Year Change
+5.5%
Year-to-Date Change
-56.7%
From 52W High of $3.12
+40.6%
From 52W Low of $0.96

๐Ÿค” Considering Cardiol (CRDL)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 8, 2025 9:43 AM UTC

CRDL Analyst Ratings & Price Targets

Based on our analysis of 5 Wall Street analysts, CRDL has a consensus that is bullish. The median price target is $8.66, with forecasts ranging from $7.84 to $9.83. Currently, there are 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.

With CRDL currently trading at $1.35, the median price forecast suggests a 541.5% upside. The most optimistic forecast comes from at , projecting a 628.2% upside, while at provides the most conservative target, suggesting a 480.8% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

CRDL Analyst Consensus

5
Buy
0
Hold
0
Sell

CRDL Price Target Range

Low
$7.84
Average
$8.66
High
$9.83
Current: $1.35

Latest CRDL Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for CRDL.

Date Firm Analyst Rating Change Price Target
Dec 18, 2024 HC Wainwright & Co. Vernon Bernardino Buy Reiterates $9.00
Nov 20, 2024 HC Wainwright & Co. Vernon Bernardino Buy Reiterates $9.00
Oct 24, 2024 HC Wainwright & Co. Vernon Bernardino Buy Reiterates $9.00
Jun 26, 2024 Roth MKM Jason Wittes Buy Initiates $10.00
Jun 14, 2024 HC Wainwright & Co. Vernon Bernardino Buy Reiterates $9.00
Jun 7, 2024 HC Wainwright & Co. Vernon Bernardino Buy Reiterates $9.00
May 23, 2024 Canaccord Genuity Edward Nash Buy Maintains $8.00
May 14, 2024 HC Wainwright & Co. Vernon Bernardino Buy Reiterates $9.00
Apr 22, 2024 HC Wainwright & Co. Vernon Bernardino Buy Initiates $9.00
Aug 14, 2023 Cantor Fitzgerald Charles Duncan Overweight Reiterates $3.00
May 19, 2023 Canaccord Genuity Edward Nash Buy Maintains $6.00
Dec 22, 2021 Canaccord Genuity Buy Initiates $0.00
Dec 22, 2021 Cantor Fitzgerald Overweight Initiates $0.00
Dec 17, 2021 Cantor Fitzgerald Charles Duncan Overweight Initiates $8.00
Dec 3, 2021 Canaccord Genuity Buy Initiates $0.00

Stocks Similar to Cardiol Therapeutics Inc.

The following stocks are similar to Cardiol based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Cardiol Therapeutics Inc. (CRDL) Financial Data

Cardiol Therapeutics Inc. has a market capitalization of $110.16M with a P/E ratio of -3.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -108.4%.

Valuation Metrics

Market Cap $110.16M
Enterprise Value $72.16M
P/E Ratio -3.1x
PEG Ratio -4.4x
Price/Sales 0.0x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin 0.0%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +25.5%
Current Ratio 2.4x
Debt/Equity 1.1x
ROE -108.4%
ROA -54.1%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Cardiol Therapeutics Inc. logo

Cardiol Therapeutics Inc. (CRDL) Company Overview

About Cardiol Therapeutics Inc.

What They Do

Develops therapies for heart diseases.

Business Model

Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, focusing on the R&D of anti-fibrotic and anti-inflammatory therapies for heart diseases. It generates potential revenue through the development and commercialization of its product candidates, including CardiolRx and CRD-38 injection, targeting conditions such as acute myocarditis and heart failure.

Additional Information

Founded in 2017 and based in Oakville, Canada, the company is currently conducting Phase II clinical trials for its lead product. It has a partnership with Meros, indicating potential for collaborative development and market expansion.

Company Information

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

0

CEO

Mr. David G. Elsley MBA

Country

Canada

IPO Year

2018

Cardiol Therapeutics Inc. (CRDL) Latest News & Analysis

CRDL stock latest news image
Quick Summary

Cardiol Therapeutics Inc. (NASDAQ: CRDL, TSX: CRDL) will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 4:00 p.m. EST. Webcast available online.

Why It Matters

Cardiol Therapeutics' presentation at a major healthcare conference may boost investor confidence, potentially impacting stock performance and attracting attention to its therapeutic developments.

Source: Newsfile Corp
Market Sentiment: Neutral
CRDL stock latest news image
Quick Summary

The Zacks Medical-Drugs industry is experiencing high innovation. Stocks CORT, AMRX, DYN, NKTR, and CRDL are suggested as potential portfolio additions.

Why It Matters

Innovation in the Zacks Medical-Drugs industry suggests potential growth, making companies like CORT, AMRX, DYN, NKTR, and CRDL attractive investment opportunities.

Source: Zacks Investment Research
Market Sentiment: Neutral
CRDL stock latest news image
Quick Summary

Cardiol Therapeutics' CEO, David Elsley, announced that their lead drug, CardiolRxโ„ข, is entering Phase III trials for recurrent pericarditis. The company focuses on heart disease therapies.

Why It Matters

The advancement of CardiolRxโ„ข into a late-stage Phase III trial signals potential market approval, which could significantly impact Cardiol Therapeutics' valuation and growth prospects.

Source: GlobeNewsWire
Market Sentiment: Neutral
CRDL stock latest news image
Quick Summary

Penny stocks offer low prices and high return potential but are often associated with scams like pump-and-dump. Many lack financial history and brand recognition, posing risks for investors.

Why It Matters

Penny stocks offer high risk and potential returns but often lead to losses due to scams and lack of transparency, making them a risky investment choice.

Source: MarketBeat
Market Sentiment: Neutral
CRDL stock latest news image
Quick Summary

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) reported positive results from its Phase II MAvERIC-Pilot study, showing sustained efficacy of CardiolRx in treating recurrent pericarditis over 26 weeks.

Why It Matters

Positive Phase II results for CardiolRx indicate strong potential for market success and revenue growth, enhancing Cardiol Therapeutics' valuation and attractiveness to investors.

Source: Proactive Investors
Market Sentiment: Positive
CRDL stock latest news image
Quick Summary

Cardiol Therapeutics (NASDAQ: CRDL) reported positive results from its Phase II MAvERIC-Pilot study on CardiolRxโ„ข for recurrent pericarditis, showing sustained pain and inflammation reduction. Next, it advances to Phase II/III trials.

Why It Matters

Positive clinical results for CardiolRxโ„ข indicate strong potential for treating recurrent pericarditis, advancing the companyโ€™s pipeline and likely boosting investor confidence in future trials.

Source: Newsfile Corp
Market Sentiment: Neutral

Frequently Asked Questions About CRDL Stock

What is Cardiol Therapeutics Inc.'s (CRDL) stock forecast for 2025?

Based on our analysis of 5 Wall Street analysts, Cardiol Therapeutics Inc. (CRDL) has a median price target of $8.66. The highest price target is $9.83 and the lowest is $7.84.

Is CRDL stock a good investment in 2025?

According to current analyst ratings, CRDL has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.35. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for CRDL stock?

Wall Street analysts predict CRDL stock could reach $8.66 in the next 12 months. This represents a 541.5% increase from the current price of $1.35. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Cardiol Therapeutics Inc.'s business model?

Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, focusing on the R&D of anti-fibrotic and anti-inflammatory therapies for heart diseases. It generates potential revenue through the development and commercialization of its product candidates, including CardiolRx and CRD-38 injection, targeting conditions such as acute myocarditis and heart failure.

What is the highest forecasted price for CRDL Cardiol Therapeutics Inc.?

The highest price target for CRDL is $9.83 from at , which represents a 628.2% increase from the current price of $1.35.

What is the lowest forecasted price for CRDL Cardiol Therapeutics Inc.?

The lowest price target for CRDL is $7.84 from at , which represents a 480.8% increase from the current price of $1.35.

What is the overall CRDL consensus from analysts for Cardiol Therapeutics Inc.?

The overall analyst consensus for CRDL is bullish. Out of 5 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.66.

How accurate are CRDL stock price projections?

Stock price projections, including those for Cardiol Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.